"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks.

Novo Nordisk has filed a federal lawsuit against Eli Lilly, alleging deceptive advertising in GLP-1 weight-loss drug marketing. Novo claims Lilly's ads unfairly compare outdated lower doses of Wegovy to higher doses of Zepbound, ignoring the FDA-approved 7.2 mg Wegovy dose (approved March 2025) which shows comparable weight loss results. Lilly maintains its ads are accurate based on the 2024 SURMOUNT-5 head-to-head trial. The lawsuit seeks an injunction, corrective advertising, and damages, though analysts believe the impact on both stocks is likely minimal.